The effects of ICRF-154 in combination with other anticancer agents in vitro View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1992-08

AUTHORS

Y Kano, T Narita, K Suzuki, M Akutsu, K Suda, S Sakamoto, Y Miura

ABSTRACT

We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment. More... »

PAGES

281-286

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1992.257

DOI

http://dx.doi.org/10.1038/bjc.1992.257

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021497993

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1503899


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Burkitt Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Division", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Screening Assays, Antitumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia-Lymphoma, Adult T-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Razoxane", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Tochigi Cancer Center, Japan", 
          "id": "http://www.grid.ac/institutes/grid.420115.3", 
          "name": [
            "Division of Medical Oncology, Tochigi Cancer Center, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kano", 
        "givenName": "Y", 
        "id": "sg:person.0603027536.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Narita", 
        "givenName": "T", 
        "type": "Person"
      }, 
      {
        "familyName": "Suzuki", 
        "givenName": "K", 
        "id": "sg:person.01202676124.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202676124.34"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Akutsu", 
        "givenName": "M", 
        "id": "sg:person.0717702563.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717702563.69"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Suda", 
        "givenName": "K", 
        "id": "sg:person.01331653227.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331653227.59"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Sakamoto", 
        "givenName": "S", 
        "id": "sg:person.014120017222.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014120017222.34"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Miura", 
        "givenName": "Y", 
        "id": "sg:person.01301423302.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301423302.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02899044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050764909", 
          "https://doi.org/10.1007/bf02899044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/226524a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014891537", 
          "https://doi.org/10.1038/226524a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077725830", 
          "https://doi.org/10.1007/bf00685528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/222384a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049481269", 
          "https://doi.org/10.1038/222384a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02897198", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032684078", 
          "https://doi.org/10.1007/bf02897198"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-08", 
    "datePublishedReg": "1992-08-01", 
    "description": "We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1992.257", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "keywords": [
      "supra-additive effect", 
      "ICRF-154", 
      "protective effect", 
      "leukemia cell lines", 
      "cell lines", 
      "anticancer agents", 
      "lymphoblastic leukemia cell line", 
      "such combined treatment", 
      "additive effect", 
      "cell growth inhibition", 
      "erythroleukaemia cell line", 
      "cytosine arabinoside", 
      "CPT-11", 
      "drug combinations", 
      "lymphoid malignancies", 
      "human leukemia cell lines", 
      "ID50 level", 
      "isobologram method", 
      "Combined treatment", 
      "mitomycin C", 
      "methotrexate", 
      "MOLT-3", 
      "MTT assay", 
      "drugs", 
      "such agents", 
      "growth inhibition", 
      "bleomycin", 
      "etoposide", 
      "cisplatin", 
      "amsacrine", 
      "doxorubicin", 
      "agents", 
      "malignancy", 
      "vincristine", 
      "arabinoside", 
      "effect", 
      "treatment", 
      "inhibition", 
      "days", 
      "combination", 
      "assays", 
      "cells", 
      "lines", 
      "levels", 
      "presence", 
      "HSB", 
      "results", 
      "method"
    ], 
    "name": "The effects of ICRF-154 in combination with other anticancer agents in vitro", 
    "pagination": "281-286", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021497993"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1992.257"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1503899"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1992.257", 
      "https://app.dimensions.ai/details/publication/pub.1021497993"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_228.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1992.257"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      89 URIs      76 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1992.257 schema:about N02c8a9f909424e059deb9ea00ceb7418
2 N1555ac78cf3043feb1c560d51ec4eaaa
3 N2db463e7907640cfb79cd430a97a2f05
4 N3bd400e643d44a5db828aa991d780a98
5 N43d1b801416a450180913bc6289f6621
6 N7efc91fc4c4548aaaed2762b7cbbd978
7 N8ac551ae1c114876be238103569df8f6
8 Ncaf0d4f831fa4cfc81335628beac5de5
9 Nf42dae5e6a8048059f2645a2181e3aa8
10 Nf5552b3d5af04384b30e69a813ede20e
11 anzsrc-for:11
12 anzsrc-for:1115
13 schema:author Na3143cc291f4442aa3316d9c9ea1833d
14 schema:citation sg:pub.10.1007/bf00685528
15 sg:pub.10.1007/bf02897198
16 sg:pub.10.1007/bf02899044
17 sg:pub.10.1038/222384a0
18 sg:pub.10.1038/226524a0
19 schema:datePublished 1992-08
20 schema:datePublishedReg 1992-08-01
21 schema:description We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N89e16e46ecdb457fb03918021080b1e6
25 Nfb4c02f78c4d4a19af9e2365fe33ffd5
26 sg:journal.1017082
27 schema:keywords CPT-11
28 Combined treatment
29 HSB
30 ICRF-154
31 ID50 level
32 MOLT-3
33 MTT assay
34 additive effect
35 agents
36 amsacrine
37 anticancer agents
38 arabinoside
39 assays
40 bleomycin
41 cell growth inhibition
42 cell lines
43 cells
44 cisplatin
45 combination
46 cytosine arabinoside
47 days
48 doxorubicin
49 drug combinations
50 drugs
51 effect
52 erythroleukaemia cell line
53 etoposide
54 growth inhibition
55 human leukemia cell lines
56 inhibition
57 isobologram method
58 leukemia cell lines
59 levels
60 lines
61 lymphoblastic leukemia cell line
62 lymphoid malignancies
63 malignancy
64 method
65 methotrexate
66 mitomycin C
67 presence
68 protective effect
69 results
70 such agents
71 such combined treatment
72 supra-additive effect
73 treatment
74 vincristine
75 schema:name The effects of ICRF-154 in combination with other anticancer agents in vitro
76 schema:pagination 281-286
77 schema:productId N7ffb82c63ed240feabb85d18c939cc73
78 N880cdab7068d432ea039fa75ccb4308e
79 Nd35c35e10ecf4289a9d1730fff151ca3
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021497993
81 https://doi.org/10.1038/bjc.1992.257
82 schema:sdDatePublished 2022-12-01T06:20
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N9f24bb28769b4909a00b0b4f007082d3
85 schema:url https://doi.org/10.1038/bjc.1992.257
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N02c8a9f909424e059deb9ea00ceb7418 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Leukemia-Lymphoma, Adult T-Cell
91 rdf:type schema:DefinedTerm
92 N118ba275f3ae407e963ada1a57fb5417 rdf:first N1e609ce41fe64599ac5d7157630d2f04
93 rdf:rest N783f5db86f3843158d6d05d845c861ff
94 N1555ac78cf3043feb1c560d51ec4eaaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Drug Interactions
96 rdf:type schema:DefinedTerm
97 N1e609ce41fe64599ac5d7157630d2f04 schema:familyName Narita
98 schema:givenName T
99 rdf:type schema:Person
100 N2db463e7907640cfb79cd430a97a2f05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Razoxane
102 rdf:type schema:DefinedTerm
103 N31538009897044e5a30cb37ab6d41d23 rdf:first sg:person.01331653227.59
104 rdf:rest Nc2efd341d13f4eee86e0668b96fa376c
105 N3bd400e643d44a5db828aa991d780a98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Burkitt Lymphoma
107 rdf:type schema:DefinedTerm
108 N4237f6c6fec14be485f2a36c745f4806 rdf:first sg:person.01301423302.39
109 rdf:rest rdf:nil
110 N43d1b801416a450180913bc6289f6621 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Drug Screening Assays, Antitumor
112 rdf:type schema:DefinedTerm
113 N783f5db86f3843158d6d05d845c861ff rdf:first sg:person.01202676124.34
114 rdf:rest N8fe297ad154a4ba88af948322f0798c8
115 N7efc91fc4c4548aaaed2762b7cbbd978 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Dose-Response Relationship, Drug
117 rdf:type schema:DefinedTerm
118 N7ffb82c63ed240feabb85d18c939cc73 schema:name doi
119 schema:value 10.1038/bjc.1992.257
120 rdf:type schema:PropertyValue
121 N880cdab7068d432ea039fa75ccb4308e schema:name pubmed_id
122 schema:value 1503899
123 rdf:type schema:PropertyValue
124 N89e16e46ecdb457fb03918021080b1e6 schema:volumeNumber 66
125 rdf:type schema:PublicationVolume
126 N8ac551ae1c114876be238103569df8f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N8fe297ad154a4ba88af948322f0798c8 rdf:first sg:person.0717702563.69
130 rdf:rest N31538009897044e5a30cb37ab6d41d23
131 N9f24bb28769b4909a00b0b4f007082d3 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Na3143cc291f4442aa3316d9c9ea1833d rdf:first sg:person.0603027536.70
134 rdf:rest N118ba275f3ae407e963ada1a57fb5417
135 Nc2efd341d13f4eee86e0668b96fa376c rdf:first sg:person.014120017222.34
136 rdf:rest N4237f6c6fec14be485f2a36c745f4806
137 Ncaf0d4f831fa4cfc81335628beac5de5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Cell Line
139 rdf:type schema:DefinedTerm
140 Nd35c35e10ecf4289a9d1730fff151ca3 schema:name dimensions_id
141 schema:value pub.1021497993
142 rdf:type schema:PropertyValue
143 Nf42dae5e6a8048059f2645a2181e3aa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Antineoplastic Agents
145 rdf:type schema:DefinedTerm
146 Nf5552b3d5af04384b30e69a813ede20e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cell Division
148 rdf:type schema:DefinedTerm
149 Nfb4c02f78c4d4a19af9e2365fe33ffd5 schema:issueNumber 2
150 rdf:type schema:PublicationIssue
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
155 schema:name Pharmacology and Pharmaceutical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1017082 schema:issn 0007-0920
158 1532-1827
159 schema:name British Journal of Cancer
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01202676124.34 schema:familyName Suzuki
163 schema:givenName K
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202676124.34
165 rdf:type schema:Person
166 sg:person.01301423302.39 schema:familyName Miura
167 schema:givenName Y
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301423302.39
169 rdf:type schema:Person
170 sg:person.01331653227.59 schema:familyName Suda
171 schema:givenName K
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331653227.59
173 rdf:type schema:Person
174 sg:person.014120017222.34 schema:familyName Sakamoto
175 schema:givenName S
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014120017222.34
177 rdf:type schema:Person
178 sg:person.0603027536.70 schema:affiliation grid-institutes:grid.420115.3
179 schema:familyName Kano
180 schema:givenName Y
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70
182 rdf:type schema:Person
183 sg:person.0717702563.69 schema:familyName Akutsu
184 schema:givenName M
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717702563.69
186 rdf:type schema:Person
187 sg:pub.10.1007/bf00685528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077725830
188 https://doi.org/10.1007/bf00685528
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/bf02897198 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032684078
191 https://doi.org/10.1007/bf02897198
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/bf02899044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050764909
194 https://doi.org/10.1007/bf02899044
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/222384a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049481269
197 https://doi.org/10.1038/222384a0
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/226524a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014891537
200 https://doi.org/10.1038/226524a0
201 rdf:type schema:CreativeWork
202 grid-institutes:grid.420115.3 schema:alternateName Division of Medical Oncology, Tochigi Cancer Center, Japan
203 schema:name Division of Medical Oncology, Tochigi Cancer Center, Japan
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...